Platelet aggregation and thromboxane A2 release in primary biliary cirrhosis and effect of D-penicillamine treatment.
Platelet function was assessed in 28 patients with primary biliary cirrhosis (PBC), of whom 10 were receiving D-penicillamine. Patients not on D-penicillamine treatment had platelet aggregation similar to that in the healthy control group; the group treated with D-penicillamine showed significantly enhanced platelet aggregation in response to threshold doses of adrenaline and collagen but not ADP. Median thromboxane B2 production was also higher in D-penicillamine treated patients than in controls or untreated patients; this difference did not reach statistical significance. The addition of D-penicillamine in vitro to platelet rich plasma from normal subjects was shown to enhance adrenaline- and collagen-induced platelet aggregation. Abnormalities of platelet function in PBC patients did not correlate with serum cholesterol concentration or with liver function tests but were related to the stage of disease. The present study emphasises the need to consider the aetiology, disease stage and type of treatment when assessing platelet function and prostanoid release in liver disease.
Mikhailidis
D P
DP
Department of Chemical Pathology and Human Metabolism, Royal Free Hospital, London, U.K.
Fonseca
V
V
Barradas
M A
MA
Hutton
R A
RA
Jeremy
J Y
JY
Epstein
O
O
McIntyre
N
N
Dandona
P
P
D000368:Aged; D002784:Cholesterol / Q000097:blood; D005260:Female; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000188:drug therapy* / Q000378:metabolism; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D010396:Penicillamine / Q000627:therapeutic use*; D010974:Platelet Aggregation / Q000187:drug effects*; D010976:Platelet Count / Q000187:drug effects; D013928:Thromboxane A2 / Q000378:metabolism*; D013929:Thromboxane B2 / Q000378:metabolism
D013929:Thromboxane B2; D013928:Thromboxane A2; D002784:Cholesterol; D010396:Penicillamine